IFN-beta Proteins, Antibodies, cDNA Clones Research Reagents

IFNB1 (Interferon Beta 1, also known as IFB; IFF; IFNB; IFN-beta), located on 9p21.3, is conserved in chimpanzee, Rhesus monkey, dog, mouse, and rat. The gene produces a 22294 Da protein composed of 187 amino acids. This gene encodes a cytokine that belongs to the interferon family of signaling proteins, which are released as part of the innate immune response to pathogens. Diseases such as Secondary Progressive Multiple Sclerosis and Primary Progressive Multiple Sclerosis are associated with IFNB1. The related pathways of IFNB1 include all-trans-retinoic Acid Mediated Apoptosis and Tuberculosis.

IFN-beta Protein (5)

    IFN-beta Antibody (9)

      IFN-beta cDNA Clone (52)

      NM_002176.2

      クローニングベクター cDNA 製品

      In lentiviral vector

      NM_010510.1

      クローニングベクター cDNA 製品

      In lentiviral vector

      NM_019127.1

      クローニングベクター cDNA 製品

      In lentiviral vector

      NM_001135795.1

      クローニングベクター cDNA 製品

      In lentiviral vector

      IFN-beta Lysate (5)

        IFN-beta の背景知識

        Interferons (IFNs) are natural glycoproteins belonging to the cytokine superfamily and are produced by the cells of the immune system of most vertebrates in response to challenges by foreign agents such as viruses, parasites, and tumor cells. Interferon-beta (IFN beta) is an extracellular protein mediator of host defense and homeostasis. IFN beta has well-established direct antiviral, antiproliferative, and immunomodulatory properties. Recombinant IFN beta is approved for the treatment of relapsing-remitting multiple sclerosis. The recombinant IFN beta protein has the theoretical potential to either treat or causes autoimmune neuromuscular disorders by altering the complicated and delicate balances within the immune system networks. It is the most widely prescribed disease-modifying therapy for multiple sclerosis (MS). Large-scale clinical trials have established the clinical efficacy of IFN beta in reducing relapses and slowing disease progression in relapsing-remitting MS. IFN beta therapy was shown to be comparably beneficial for opticospinal MS (OSMS) and conventional MS in Japanese. IFN beta is effective in reducing relapses in secondary progressive MS and may have a modest effect in slowing disability progression. In addition to the common antiviral activity, IFN beta also induces increased production of the p53 gene product which promotes apoptosis and thus has a therapeutic effect against certain cancers. The role of IFN-beta in bone metabolism could warrant its systematic evaluation as a potential adjunct to therapeutic regimens of osteolytic diseases. Furthermore, IFN beta might play a beneficial role in the development of chronic progressive CNS inflammation.

        IFN-beta の参考文献

        • Kohriyama T, et al. (2008) Interferon-beta treatment for multiple sclerosis and predictors of response. Nippon Rinsho. 66(6): 1119-26.
        • Stbgen JP. (2009) Recombinant interferon-beta therapy and neuromuscular disorders. J Neuroimmunol. 212(1-2): 132-41.
        • Abraham AK, et al. (2009) Mechanisms of interferon-beta effects on bone homeostasis. Biochem Pharmacol. 77(12): 1757-62.

        Note: Flag® is a registered trademark of Sigma Aldrich Biotechnology LP. It is used here for informational purposes only.